- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03258658
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral
This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males.
The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males.
The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular Polyglycolic Acid (PGA) scaffolds to create autologous urethral constructs for the repair of urethral strictures.
Male patients, aged 21-65 years old, seen in the Wake Forest Baptist Health urology clinic, referred to or self-referred to the study team, with recurrent urethral stricture, previously treated with dilation, internal urethrotomy, or urethroplasty, will be approached and offered consent to participate in in the trial. Up to 20 men may undergo screening procedures to identify 10 eligible subjects meeting all inclusion and exclusion criteria. All eligible subjects will undergo full thickness bladder tissue biopsies at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina to obtain UCs and SMCs, which will be cultured and expanded and then seeded on tubular PGA scaffolds. Approximately 6 weeks after biopsy, the subjects will return to undergo surgical removal of the stricture and implant of the urethral construct. Subjects will be followed through 36 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Mary-Clare Day, RN, BSN
- Phone Number: 336-713-1343
- Email: mday@wakehealth.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- University of California San Francisco
-
Principal Investigator:
- Benjamin Breyer, MD
-
Contact:
- Natalie Rios
- Phone Number: 415-723-1456
- Email: Natalie.Rios@ucsf.edu
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Institute for Regenerative Medicine (WFIRM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Stricture of the anterior urethra meeting the following criteria:
- History of at least one previously failed attempt at conservative management, at least 6 months prior to study.
- Urethral stricture of 10-60 mm in length, as determined by urethrography.
- Contains at least 1 strictured segment through which a 16 Fr flexible cystoscope cannot be atraumatically passed.
- Patients must be available for all follow-up visits.
- Ability to speak English.
Exclusion Criteria:
- Strictures of the meatus or prostatic urethra; any urethral stricture associated with or suspected to be urethral carcinoma, or strictures due to pelvic distraction injuries. Strictures <10 mm or >60 mm, as determined by urethrography, and criteria for bulbar urethral strictures excluding those with strictures <20 mm and >60 mm, as described by urethrography.
- Presence of untreated urinary tract infection.
- Presence or prior history of lichen sclerosus et atrophicus (previously termed 'balanitis xerotica obliterans').
- Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.
- Any urological condition that would be likely to require additional urethral instrumentation during the period of investigation, including, but not limited to benign prostatic hyperplasia requiring treatment, use of alpha blockers, active prostate cancer, an unevaluated elevated prostate surface antigen (PSA), bladder cancer, or any recurrent urinary stone formation. Patients with evidence or diagnosis of any coagulation disorder (including concomitant anti-coagulation therapy at enrollment).
- Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease.
- Patients with abnormal urologic conditions, including vesicoureteral reflux, bladder stones, bladder tumors and renal impairment.
- Subjects with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >3 times the upper limit of normal.
- Subjects with an albumin value <3.0 g/dL.
- Subjects with uncontrolled diabetes, unstable cardiac and/or pulmonary disorders.
- Subjects with active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.
- Subjects known to be colonized with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.
- Immunocompromised subjects or subjects receiving immunosuppressive agents (inhaled corticosteroids and chronic low-dose corticosteroids [≤0.25 mg/kg prednisone or equivalent per day] are permitted).
- Any history of alcohol and/or drug abuse.
- Current smoker.
- Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV).
- Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.
- Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.
- Any current illness that might confound the results of this investigation, including but not limited to bladder atonia, neuropathic/neurogenic bladder, bladder outlet obstruction (other than urethral stricture), sphincteric dysfunction, or spinal cord injury.
- Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.
- Inability to participate in all necessary study activities due to physical or mental limitations.
- Inability or unwillingness to return for all required follow-up visits.
- inability or unwillingness to sign informed consent.
- Patients requiring concomitant use of or treatment with immunosuppressive agents.
- Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Engineered Urethral Construct
All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure.
Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct.
Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct.
All subjects will be followed for 3 years for safety and efficacy.
|
urethral construct
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of product-related, biopsy procedure-related, and injection procedure-related adverse events
Time Frame: monitored through 36 months post treatment
|
Rate of adverse events reported for each patient
|
monitored through 36 months post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of urethral construct in repairing urethral stricture
Time Frame: monitored through 36 months post construct implant
|
Improvement in peak urinary flow rate defined as Qmax improvement from baseline
|
monitored through 36 months post construct implant
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: James Yoo, MD, Wake Forest Institute for Regenerative Medicine
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00043624
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urologic Diseases
-
University Hospital, GhentCompletedSurgery | Bladder Cancer | Urologic CancerBelgium
-
Chang Gung Memorial HospitalCompleted
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaboratorsRecruiting
-
Diskapi Yildirim Beyazit Education and Research...Unknown
-
Fundación Pública Andaluza para la gestión de la...RecruitingSurgery | Anesthesia | Urologic CancerSpain
-
IRCCS San RaffaeleRecruitingUrologic Diseases | Infertility | Urologic CancerItaly
-
Changhai HospitalUTC Therapeutics Inc.RecruitingCD70-positive Advanced Urologic NeoplasmsChina
-
Yonsei UniversityCompletedPediatric Urologic SurgeriesKorea, Republic of
-
Yonsei UniversityCompletedElective Urologic SurgeriesKorea, Republic of
-
Kasr El Aini HospitalUnknownUrologic Surgical ProceduresEgypt
Clinical Trials on Autologous Engineered Urethral Construct
-
I.M. Sechenov First Moscow State Medical UniversityUnknownUrethral StrictureRussian Federation
-
A.A. Partners, LLCUnknown
-
TengionWithdrawnOveractive BladderUnited States
-
TengionTerminated
-
TengionTerminatedNeurogenic BladderUnited States
-
Institut National de la Santé Et de la Recherche...Active, not recruitingEpidermolysis Bullosa Dystrophica, RecessiveFrance
-
Wake Forest University Health SciencesUnited States Department of DefenseNot yet recruitingUrologic Diseases | Trauma Injury | Penile Diseases | Male Urogenital Diseases | Corpus Callosum Malformation | Corpora Cavernosa; InflammationUnited States
-
Ankara Training and Research HospitalCompletedSurgery--Complications | Stress Urinary Incontinence
-
Abeona Therapeutics, IncNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedEpidermolysis Bullosa | Epidermolysis Bullosa DystrophicaUnited States
-
Abeona Therapeutics, IncCompletedEpidermolysis Bullosa | Recessive Dystrophic Epidermolysis BullosaUnited States